Pharmaceuticals giant GlaxoSmithKline (GSK) has acquired five million newly-issued shares in Response Genetics, taking its stake in the company to around 15.2 per cent.
GSK purchased the shares at 110 cents each in cash.
"This transaction builds on the relationship GSK and Response Genetics have been building over the years in the diagnostics field of oncology and vaccines," the firm said in a statement.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Response Genetics performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.
GSK's share price rose 0.91% to 1,434.50p by 14:52.
NR
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
